I placebo- kontrollerede kliniske forsøg med abatacept indberettedes bivirkninger hos 52, 2% af de abataceptbehandlede patienter og hos 46, 1% af de placebobehandlede.
In placebo-controlled clinical trials with abatacept, adverse drug reactions (ADRs) were reported in 52.2% of abatacept-treated patients and 46.1% of placebo-treated patients.